Potential of Novel EPO Derivatives in Limb Ischemia by Joshi, Dhiraj et al.
Hindawi Publishing Corporation
Cardiology Research and Practice
Volume 2012, Article ID 213785, 5 pages
doi:10.1155/2012/213785
Review Article
Potential of Novel EPO Derivatives in LimbIschemia
DhirajJoshi,1 JaniceTsui,1 Rebekah Yu,1 Xu Shiwen,2 SadasivamSelvakumar,1
DavidJ. Abraham,2 and DaryllM. Baker1
1Vascular Unit, Division of Surgery and Interventional Science, Royal Free Hospital, University College London (Royal Free Campus),
Pond Street, London NW3 2QG, UK
2Centre for Rheumatology, University College London (Royal Free Campus), Pond Street, London NW3 2QG, UK
Correspondence should be addressed to Janice Tsui, janice.tsui@ucl.ac.uk
Received 15 July 2011; Accepted 12 December 2011
Academic Editor: Sidney G. Shaw
Copyright © 2012 Dhiraj Joshi et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Erythropoietin (EPO) has tissue-protective properties, but it increases the risk of thromboembolism by raising the haemoglobin
concentration. New generation of EPO derivatives is tissue protective without the haematopoietic side eﬀects. Preclinical studies
have demonstrated their eﬀectiveness and safety. This paper summarizes the development in EPO derivatives with emphasis on
their potential use in critical limb ischaemia.
1.Introduction
Critical limb ischaemia (CLI) causes considerable morbidity
and mortality. Surgical and endovascular revascularization
are the main treatment options. One-fourth of patients pre-
senting with CLI undergo a major amputation, primarily
because they are not suitable for revascularization [1]. Phar-
macotherapy has negligible role in the management of CLI.
Prostacyclin is the only disease-modifying drug with proven
eﬃcacy in reducing rest pain and/or ulcer size in CLI via its
vasodilatory eﬀects on the distal circulation [2]. The Trans-
Atlantic Inter Society Consensus document on peripheral
vasculardisease(TASC)hasrecommendedtheuseofiloprost
in CLI to avoid or delay major amputation [3]. There is lim-
ited evidence supporting the use of other vasoactive drugs
such as pentoxifylline, cilostozol, and L-Arginine (precursor
of nitric oxide) in the treatment of CLI [4].
More recently, the possibility of using recombinant for-
mulations of growth factors to augment the development of
collateralsandnewcapillariesfrompre-existingbloodvessels
has been explored. This is otherwise known as therapeu-
tic angiogenesis [5]. Prominent among these techniques
is the intra-arterial or intramuscular administration of
vascular endothelial growth factor (VEGF) plasmid DNA
(phVEGF165)[ 6] where initial studies in patients with CLI
demonstrated an increase in angiogenesis [7]. Other than
gene therapy, clinical studies have been carried out to inject
bone-marrow mononuclear cells intramuscularly in CLI.
The innate ability of bone marrow cells to supply endothelial
progenitor cells and release endothelial growth factors and
cytokines also helped induce angiogenesis [8]. However, de-
spite a demonstration of increased angiogenesis, improve-
ment in clinical endpoints was less clear. This is likely to be
due to the complex pathology involved within the ischaemic
tissue [9].
Tissue protection may be an alternative therapeutic strat-
egy for CLI where reducing tissue damage and maintaining
tissue viability may improve outcome of current treatments
and contribute to limb salvage. It has been shown previously
that limb ischaemia causes apoptosis of skeletal muscle [19].
T h e r e f o r e ,t h eu s eo ft i s s u ep r o t e c t i v ea g e n t st od e c r e a s e
apoptosis and inﬂammation, either alone or in combination
with other therapeutic strategies, may be beneﬁcial.
Erythropoietin (EPO) has tissue protective properties
thathavebeendescribedextensively[20,21].Wehaverecent-
ly shown that there is expression and upregulation of EPO
receptors (EPORs) in human skeletal muscle [18]. However,
EPO triggers profound haematopoiesis that increases the
risk of thromboembolism [22]. This may prevent its use in
CLI. Lately, nonhematopoietic EPO derivatives have been
developed, which avoid its hematopoietic side eﬀects [23].
The aim of this paper is to summarize the developments that2 Cardiology Research and Practice
have taken place so far in the use of EPO derivatives in pro-
tection of ischaemic tissue and discuss its potential use in
CLI.
2.EPOandItsReceptors
Erythropoietin (EPO) belongs to the class-I cytokine family.
It is a glycoprotein hormone with a molecular mass of
30.4kDa [24]. The protein core contains 165 amino acids
and the peripheral carbohydrate chains are made up of 4 N-
linked oligosaccharides (Figure 1)[ 25].
Human EPO receptor (EPOR) is a cell surface protein
containing 508 amino acids and has a molecular weight of 55
KDa[26].Itbelongstothecytokinereceptorsuperfamilyand
contains extracellular, transmembraneous, and intracellular
domains [27]. The common β-chain of IL-3/IL-5/GM-CSF
receptor (also called CD131 or β-common receptor) belongs
to the same super-family. The molecular weight of β-com-
mon receptor (βcR) is approximately 130kDa [23]. The EPO
molecule binds to two EPOR subunits (EPOR dimers or
(EPOR)2) to bring about the haemopoietic action. In con-
trast, the EPO molecule binding to two βcR subunits sand-
wiching two EPOR subunits mediates the tissue protective
function [23]. The four subunits constitute the heterorecep-
tor complex, which binds to the EPO molecule and activates
cell signalling (Figure 2). The intracellular or cytoplasmic
domain of all cytokine receptors is intangibly related to a
Janus family tyrosine protein kinase 2 (JAK2). The binding
ofEPOtoitsreceptor(EPORhomodimerorβcRandEPOR)
induces a conformational change in the receptor, activating a
downstream signalling pathway that leads to the transcrip-
tion of new proteins that determine the fate of the cell [28].
Endogenous EPO is essential for the maturation and
survival of erythrocytes and thus maintaining the normal
haemoglobinconcentration.Inchronicrenalfailure,thekid-
neys cease to make EPO, and commercially available prepa-
rations of recombinant human EPO (rHuEPO) are mainly
used to treat anaemia secondary to chronic renal failure [30].
In addition to its role in prolonging the survival of erythro-
cytes, EPO has been shown to exert anti-apoptotic and anti-
inﬂammatoryeﬀectsinneuralandcardiactissuebothinvitro
and in vivo. Clinical trials have also conﬁrmed its beneﬁcial
eﬀects in stroke and myocardial infarction [21, 31].
However, the ability of rHuEPO to bond with EPOR in
extrahaematopoietic tissues including vascular endothelium
is about 50 times less than that in the erythroid cells [32].
Hence, the dose of EPO required to attain a tissue protective
eﬀect in heart and brain ischaemia is much higher than that
used for the management of anaemia in renal failure. In CLI,
the volume of ischaemic tissue is even greater than that in
heart and brain ischaemia, therefore higher doses still may
be required to achieve a therapeutic eﬀect. This will cause an
unfavorable increase in the haematocrit and blood viscosity,
which in turn will raise the risk of thromboembolism and
occlusion of arteries with pre-existing disease [33, 34]. An-
otherconcernisapotentialeﬀectontumourprogressiondue
to its angiogenic properties [35]. However, recent evidence
suggests that this may not be a signiﬁcant risk [36]. EPO also
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Figure 1: A schematic representation of the molecule of EPO.
Adapted from Elliott et al. [25]
causes hypertension by its action on vascular smooth muscle
cells [37–39].
Due to the potential side eﬀects, most research on the
tissue protective eﬀects of EPO in CLI and other tissues has
been limited to preclinical models. However, the latest non-
haemopoietic EPO derivatives may overcome the unneces-
sary side eﬀects and permit the translation of preclinical re-
sults into clinical trials [11].
3. Nonhaematopoietic Derivativesof EPO
3.1. Carbamylated Erythropoietin (CEPO). CEPO is formed
by the chemical modiﬁcation of the amino acid lysine to
homocitrulline. It changes the receptor-binding capability of
the EPO molecule [11].
3.2. Asialo EPO. Asialo EPO is formed by decreasing the
sialic acid content of rHuEPO by a technique known as the
total enzymatic desialylation. Remarkably, the molecule re-
tainsitstissueprotectiveproperty butlosesthehaemopoietic
ability. This also results in the reduction of the half-life of the
Asialo EPO to minutes [10].
3.3. Helix-B Surface Peptide (HBSP) [40]. The EPO mol-
ecule, a glycoprotein that contains 165 amino acids is folded
in such a way that the hydrophobic areas-helixes A, C, and D
face away from the surface and are embedded in the extra-
cellular domains of (EPOR)2.H o w ev e r ,h e l i xBt h a ti sh y d r o -
philic points away from the receptor and has wide-ranging
tissue-protective properties. Isolating the helix B which is
devoid of the primary sequence resulted in a low molecu-
lar weight peptide. The spontaneous cyclization of Helix BCardiology Research and Practice 3
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Figure 2: Schematic representation of the structure of erythropoietin receptor (EPOR) and beta-common receptor (CD131) on the left and
the right hand side, respectively. ∗Based on Brines et al. [29]. JAK-2 stands for Janus family Tyrosine Protein Kinase 2.
Table 1: Recent studies investigating the role of nonhaematopoietic derivatives of EPO.
Author Nonhaematopoietic
EPO derivative Model Inference
Erbayraktar et al. 2003 [10] Asialo EPO In vivo model of cerebral and spinal
cord ischaemia plus sciatic nerve injury Neuroprotection-recovery of paraplegia
Leis et al. 2004 [11] Carbamylated
EPO (CEPO)
In vitro and in vivo models of neural
injury
Demonstration of tissue protective
properties of CEPO in neural tissue
Fiordaliso et al. 2005 [12] CEPO In vivo model of rat myocardial
infarction
Reduction in the size of
myocardial infarct
Fantacci et al. 2006 [13] CEPO In vivo model of metabolic stress in
mice induced by chronic hypoxia (CH)
CEPO reduced metabolic stress caused
b yC Ha n di m p r o v e dc e l l u l a rs u r v i v a l
independent of haematopoiesis.
Erbayraktar et al. 2006 [14] CEPO In vivo model of radiosurgically induced
brain injury in rats Decreased necrosis of the brain tissue
Erbayraktar et al. 2009 [15] CEPO and ARA 290 In vivo models of decubitus ulcers
and peritonitis
Improved healing and less intraperitoneal
adhesion formation
Ahmet et al. 2010 [16] ARA 290 In vivo model of myocardial ischemia Reduction in the size of infarct and
improvement of ejection fraction
Joshi et al. 2010 [17] ARA 290 In vitro Decreased apoptosis of myotubes but
no eﬀect on angiogenesis
Joshi et al. 2011 [18] ARA 290 In vitro Decreased ischaemia-induced
inﬂammation and apoptosis of myotubes
surface peptide (HBSP) gives rise to pyroglutamate HBSP
(pHBSP), which is also known as ARA 290. The eﬀective
dose of ARA 290 peptide that showed evidence of tissue
protection was comparable on a molar basis to those studied
forEPOandwashigherthanthatrequiredforEPO-mediated
erythropoiesis. For example, in the renal ischaemia model of
mice, 0.08nmol/kg of bw (equivalent to 300 units/kg of body
weightofEPO)wasineﬀective,whereasa10-foldhigherdose
elicited strong tissue protection [40]. The studies of non-
erythropoietic EPO derivatives have been summarised in
Table 1.
4. Mechanismof Action
Receptor-initiated cell signaling by EPO and its derivatives
occurs via multiple molecular cascades, which diﬀer in4 Cardiology Research and Practice
importance depending on the speciﬁc tissue or cell type, as
well as the type of injury [41]. As in erythropoiesis, the
majority of tissue-protective responses begin by the phos-
phorylation of JAK-2 or JAK-1 [42, 43]. Following JAK-2
phosphorylation,3mainpathwaysareactivatedthatresultin
attenuation of apoptosis: STAT-5/Bcl-xL (Signal Transducers
andActivatorofTranscription;type5)[44];PI3K/Akt(phos-
phatidyl inositol-3 kinase/Protein Kinase B) [45]; in some
tissues including the heart, the MAPK (mitogen-activated
protein kinase) pathway is involved [46]. MAPK and P13K/
Akt inhibit caspase activation, thus directly attenuating
apoptosis. We have shown that ARA 290 decreases cleaved
caspase-3 in the myotubes subjected to ischaemia [18]. This
may indicate that EPO and its derivatives may attenuate
apoptosis through the MAPK or P13K/Akt pathway. How-
ever, further study is needed to understand completely the
interactions of these signaling pathways that ultimately
transduce tissue protection in vivo.
5. Discussion
It is now known that EPO receptors are present in human
skeletal muscle and their expression is elevated in CLI. It
has also been shown that a nonhaematopoietic derivative of
EPO (ARA 290) decreases inﬂammation and apoptosis of
ischaemic myotubes and may thus be used to selectively en-
hance the tissue-protective activity of EPO whilst avoiding
the haematopoietic side eﬀects in CLI.
The timing of administering EPO derivatives depends on
theirhalf-life.CEPOhasahalf-lifeof4–6hourswhileAsialo-
EPO and ARA 290 have a half-life of about 2 minutes. Most
in vivo studies have treated animals immediately following
ischaemic injury [15, 23]. In the context of CLI, EPO deriva-
tives may be used at the onset of CLI, either alone or as an
adjunct to surgical or endovascular revascularization via sys-
temic administration through intra-arterial, intravenous, or
intramuscular routes. Due to the relatively short half-life of
currently available compounds, repeated injections may be
required. Clinical studies are needed to assess the eﬃcacy of
EPO derivatives in patients with CLI and to identify optimal
delivery routes and dosing schedules.
6. Conclusion
EPOreceptorsarepresentinhumanskeletalmuscleandtheir
expression is elevated in CLI. Nonhaematopoietic derivatives
of EPO decrease inﬂammation and apoptosis of ischaemic
myotubes whilst avoiding haematopoietic side eﬀects. They
may thus reduce tissue damage and provide a unique ther-a-
peutic alternative for CLI.
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